Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
Globe Newswire•06/11/2026•16:01 ET
0
Key Highlights
- ➤Nkarta will webcast initial NKX019 clinical data on November 9, 2026
- ➤NKX019 is being evaluated in myositis and systemic sclerosis
- ➤Ntrust trials assess safety and durable remission potential in autoimmune diseases
- ➤Ntrust programs use CD19-targeted CAR-NK therapy after lymphodepletion
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET, to review initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis being presented at the American College of Rheumatology (ACR) Convergence 2026 in Orlando.
Live Webcast To access the webcast, please register through this link: https://nkarta-clinical-update-acr-convergence-2026.open-exchange.net/
Get started
Create a free account to read the full story.